Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 New regimens and directions in the management of newly diagnosed multiple myelomaAmerican Journal of Hematology.  96:367-378. 2021
2021 Autologous stem cell transplantation in the age of ANDROMEDABritish Journal of Haematology2021
2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - ReplyJAMA Oncology2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationBone Marrow Transplantation2021
2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLeukemia.  35:18-30. 2021
2020 Age is just a number, the wrong numberCancer.  126:5014-5016. 2020
2020 Solid Organ Transplantation 2020
2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaBiology of Blood and Marrow Transplantation.  26:1394-1401. 2020
2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisJAMA Oncology.  6:1759-1765. 2020
2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline ChemoimmunotherapyBiology of Blood and Marrow Transplantation2020
2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myelomaBritish Journal of Haematology.  186:807-819. 2019
2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myelomaCancer Immunology Research.  7:1224-1229. 2019
2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancerJournal of Surgical Oncology.  114:323-328. 2016
2015 Myocardial perfusion imaging determination using an appropriate use smartphone applicationJournal of Nuclear Cardiology.  22:66-71. 2015
2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal MetastasisRivista di Neuroradiologia.  27:685-689. 2014
2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancerNuclear Medicine Communications.  32:52-58. 2011

Investigator On

  • Private Grant  awarded by CELGENE CORPORATION 2021 - 2026
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2021 - 2026
  • Private Grant  awarded by Genentech 2020 - 2025
  • Private Grant  awarded by JUNO THERAPEUTICS 2021 - 2025
  • UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by SUTRO BIOPHARM 2020 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2021 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2021 - 2024
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2020 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2021 - 2024
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2021 - 2024
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2020 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by AMGEN, INC.^ 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012
  • Full Name

  • Susan Bal